PV
Pierre A. Van Damme
Highly rated in
26
conditions

Pierre A. Van Damme

Vaxinfectio - Antwerp University
Belgium
Highly rated in
26
conditions
Highly rated in
26
conditions
About|Expertise|Location|Research
Areas of Expertise

Many experts have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a expert treats and their level of experience.

Check Pierre A. Van Damme's experience treating your condition:
About Pierre A. Van Damme

Pierre Van Damme practices in Antwerp, Belgium. Van Damme is highly rated in 26 conditions, according to our data. His top areas of expertise are Hepatitis A, Tetanus, Human Papillomavirus Infection, Hepatitis, and Liver Transplant.

His clinical research consists of co-authoring 355 peer reviewed articles and participating in 18 clinical trials in the past 15 years.

Locations
Antwerp, BE
Background & Education
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials
Study for the Development of Standard Operating Procedures for Anti-HPV Antibody Detection in First-void Urine: the AB-SOP Follow-up Study
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Other
Detection of Biomarkers in First-void Urine Samples for Follow-up of Women Treated for High-grade Cervical Intraepithelial Neoplasia (CIN)
Enrollment Status: Active, not recruiting
Publish Date: November 04, 2022
Intervention Type: Device
A First-in-human Phase I, Single Center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Safety and Immune Response of Increasing Doses of OVX836 Vaccine After Intramuscular (IM) or Intranasal (IN) Administrations in Healthy Subjects Aged 18-49 Years.
Enrollment Status: Completed
Publish Date: September 22, 2022
Intervention Type: Biological
Study Phase: Phase 1
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Enrollment Status: Completed
Publish Date: August 05, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
Developing a Complete Cervical Cancer Screening Solution Based on First-void Urine Self-sampling: Validation for Detection of Precursor Lesions
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Placebo-controlled Trial to Evaluate the Optimal Dose of MV-LASV, a New Vaccine Against LASSA Virus Infection, Regarding Safety, Tolerability & Immunogenicity in Healthy Volunteers Consisting of an Unblinded Dose Escalation & an Observer-blinded Treatment Phase
Enrollment Status: Completed
Publish Date: January 24, 2022
Intervention Type: Biological, Other
Study Phase: Phase 1
Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?
Enrollment Status: Active, not recruiting
Publish Date: December 08, 2021
Intervention Type: Diagnostic Test
Study Phase: Not Applicable
A Phase 2, Partial Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of Two Novel Live Attenuated Serotype 2 Oral Poliovirus Vaccines Candidates, in Healthy Adults Previously Vaccinated With Oral Polio Vaccine (OPV) or Inactivated Polio Vaccine (IPV), Compared With Historical Controls Given Sabin OPV2 or Placebo
Enrollment Status: Completed
Publish Date: October 15, 2021
Intervention Type: Biological
Study Phase: Phase 2
Developing Methods to Investigate Additional Opportunities of HPV Vaccination, Including Control of Infection and Transmission, by Using a Cervicovaginal Human Sample, Collected by Urination (HPV-VACPLUS)
Enrollment Status: Completed
Publish Date: September 29, 2021
Intervention Type: Other
A Phase 1, Blinded, Single Center Study to Evaluate the Safety and Immunogenicity of Two Novel Live Attenuated Serotype 2 Oral Poliovirus Vaccines, Derived From a Modified Sabin 2 Infectious cDNA Clone, in Healthy Adults Previously Primed With Inactivated Polio Vaccine (IPV)
Enrollment Status: Completed
Publish Date: February 04, 2021
Intervention Type: Biological
Study Phase: Phase 1
Developing a Complete Cervical Cancer Screening Solution Based on First-void Urine Self-sampling: Improved and Quality Assured Collection of First-void Urine
Enrollment Status: Completed
Publish Date: July 21, 2020
Intervention Type: Device
Study Phase: Not Applicable
Immunogenicity and Safety of HBAI20 Hepatitis B Vaccine in Non-responders
Enrollment Status: Completed
Publish Date: January 31, 2019
Intervention Type: Biological
Study Phase: Phase 2
Collection of First-void Urine Samples for the Development of Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine: the AB-SOP Study
Enrollment Status: Completed
Publish Date: June 15, 2017
Intervention Type: Other
Collection of First-void Urine Samples for the Development of Standard Operating Procedures for Cervical (Pre)Cancer Biomarker Detection in First-void Urine: the BM-SOP Study
Enrollment Status: Completed
Publish Date: June 15, 2017
Intervention Type: Other
Proof Of Concept Study: Immunogenicity and Safety of Hepatitis B Injection in the Dermis in Healthy Volunteers Using an Intradermal Injection Device (VAX-ID)
Enrollment Status: Completed
Publish Date: March 28, 2017
Intervention Type: Drug, Device
Study Phase: Phase 1
A Phase II Open, Randomised, Controlled Study to Evaluate the Safety and Immunogenicity of a Paediatric Dose (0.25 mL) and the Standard Dose (0.5 mL) of Epaxal® With Reference to Havrix Junior® Healthy in Healthy Children and Adolescents (>=12 Months - 16 Years of Age) Using a 0/6 Month Schedule
Enrollment Status: Completed
Publish Date: July 29, 2014
Intervention Type: Biological
Study Phase: Phase 2
A Phase 2, Open-label, Single-center, Extension Study to Evaluate the Booster Response Induced by Vi-CRM197 After Priming With Either Vi-CRM197 or Typherix Administered in Adult Subjects in H01_04TP Study (NCT01193907)
Enrollment Status: Completed
Publish Date: March 24, 2014
Intervention Type: Biological
Study Phase: Phase 2
A Pilot, Controlled, Comparative and Single Blinded Study to Evaluate the Safety and Immunogenicity of Low Dose Flu Vaccines Administered Intradermally Using Microneedle Injectors as Compared With Standard Dose Intramuscular Flu Vaccines as Reference.
Enrollment Status: Completed
Publish Date: May 10, 2013
Intervention Type: Biological
Study Phase: Not Applicable
View 17 Less Clinical Trials -
355 Total Publications
Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up.
Journal: BMJ open
Published: September 19, 2022
Save this expert for later
Sign Up
Looking for the best expert for you?
Start Here
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more